Precision and Personalized Medicine in Pharma – Thematic Intelligence

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$1950
Buy Report View Sample

Published: June 30, 2023 Report Code: GDHCHT411-TH

Select Item

Precision and Personalized Medicine in Pharma Thematic Report Overview

Precision and personalized medicine have already begun to reshape disease treatment paradigms and the provision of healthcare. Improved patient outcomes, increased quality of life, reduced financial and time expenditure of disease management with curative therapies, and a shift from reactive to proactive care are all driving investment in R&D in this space.

The precision and personalized medicine in pharma thematic intelligence report provides a focused chapter on the key healthcare, technology, macroeconomic, and regulatory trends impacting precision and personalized medicine. The report also reviews how these trends will accelerate or hinder precision and personalized medicine.

Report Pages 62
Regions Covered Global
Market Size (2022) $8 billion
CAGR (2022-2029) >43%
Key Trend ·       Healthcare

·       Technology

·       Macroeconomic

·       Regulatory
Value Chain ·       Diagnostics

·       Therapeutics

·       Services
Leading Public Companies ·       Agilent Technologies

·       Alaunos Therapeutics

·       Alnylam Pharmaceuticals
Leading Private Companies ·       Acepodia

·       Certis Oncology Solutions

·       Complement Therapeutics
Enquire & Decide Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase.

Precision and Personalized Medicine in Pharma – Trends

The main trends shaping the personalized and precision medicine theme over the next 12 to 24 months are healthcare, technology, macroeconomic, and regulatory.

Healthcare trends: Gene therapy, cell therapy, and the success of RNA-based therapeutics are some of the key healthcare trends shaping the personalized and precision medicine theme.

Technology trends: Advancements in Big data analytics, AI, and digital twins are some of the key technology trends accelerating the growth of precision and personalized medicine.

Macroeconomic trends: Challenges such as drug prices, market access, and inflation are hindering the development and adoption of precision and personalized medicine. Additionally, M&A’s and the rising influence of China in the market are some of the key macroeconomic trends shaping the personalized and precision medicine theme.

Regulatory trends: Regulation of precision and personalized medicines and challenges in drug reimbursement are some of the key macroeconomic trends shaping the personalized and precision medicine theme.

Precision and Personalized Medicine in Pharma – Industry Analysis

The precision and personalized medicine market was valued at $8 billion in 2022. The market is expected to achieve a CAGR of more than 43% between 2022 and 2029. In 2022, antisense oligonucleotides were the largest segment and had the highest number of marketed drugs. The major growth in this field will be driven by the forecast growth in sales of Legend Biotech’s Carvykti and BMS’s Breyanzi (lisocabtagene maraleucel), as well as the expected approval of new drugs.

Global Precision and Personalized Medicine Market Revenue Segmented by Products and Services 2022-2029 ($ Billion)

Global Precision and Personalized Medicine Market Revenue Segmented by Products and Services 2022-2029 ($ Billion)

For more insights into the precision and personalized medicine in pharma market forecast, download a free report sample

Precision and Personalized Medicine in Pharma - Value Chain Analysis

The precision and personalized medicine value chain is split into five segments which are diagnostics, therapeutics, and services.

Diagnostics: Precision and personalized medicines are established on a patient’s specific biomarkers, whether they are genetic, epigenetic, proteomic, metabolomic, digital, or otherwise. Diagnostic biomarkers, which detect the presence of a disease or a predisposition towards a disease; prognostic biomarkers, which identify the likelihood of disease progression or recurrence; and predictive biomarkers, which predict a patient’s response to a particular therapy, are all fundamental in tailoring treatment.

Precision and Personalized Medicine Value Chain Analysis

Precision and Personalized Medicine Value Chain Analysis

For more insights into the precision and personalized medicine value chain, download a free report sample

Leading Precision and Personalized Medicine Public Companies

Some of the leading public pharma companies currently deploying precision and personalized medicine are:

  • Agilent Technologies
  • Alaunos Therapeutics
  • Alnylam Pharmaceuticals

Leading Precision and Personalized Medicine Private Companies

Some of the leading private pharma companies currently deploying precision and personalized medicine are:

  • Acepodia
  • Certis Oncology Solutions
  • Complement Therapeutics

To know more about the leading precision and personalized medicine companies, download a free report sample

Pharma Sector Scorecard

At GlobalData, we use a scorecard approach to predict tomorrow’s leading companies within each sector. Our sector scorecard has three screens: a thematic screen, a valuation screen, and a risk screen.

  • The thematic screen ranks companies based on overall leadership in the 10 themes that matter most to their industry, generating a leading indicator of future performance.
  • The valuation screen ranks our universe of companies within a sector based on selected valuation

metrics.

  • The risk screen ranks companies within a particular sector based on overall investment risk.

Pharma Sector Scorecard – Thematic Screen

Pharma Sector Scorecard – Thematic Screen

To know more about the sector scorecards, download a free report sample

Scope

  • A focused chapter on the key healthcare, technology, macroeconomic, and regulatory trends impacting precision and personalized medicine, and a review of how these trends will accelerate or hinder precision and personalized medicine.

  • Industry analysis and market forecast for different therapies within precision and personalized medicine up to 2029.

  • Case studies provide in-depth insight into some of the most recent and most influential developments in precision and personalized medicine, from recently approved gene therapies to new AI platforms to accelerate the development of new personalized drugs.

  • Review of leaders and disruptors across the precision and personalized medicine value chain, covering diagnostics, therapeutics, and services.

  • Thematic scorecard for drug development ranking companies on their investment in the top ten themes impacting the industry, one of which being precision and personalized medicine.

Reasons to Buy

  • Understand the key trends accelerating or hindering the precision and personalized medicine space.

  • See market forecasts for different therapies within precision and personalized medicine up to 2029.

  • Understand recent and influential developments in precision and personalized medicine.

  • Review of leaders and disruptors across the precision and personalized medicine value chain.

Roche
Illumina
Agilent Technologies
Abbott
Myriad Genetics
Thermo Fisher Scientific
Guardant Health
Tempus Labs
Ocean Genomics
Nicheri Biosciences
Certis Oncology Solutions
Novartis
Merck & Co
Johnson & Johnson
Moderna
Gilead Sciences
CRISPR Therapeutics
Bristol Myers Squibb
Roche
Sarepta Therapeutics
Alaunos Therapeutics
BrainStorm Cell Therapeutics
OncoSec Medical
Rocket Pharmaceuticals
Vor Biopharma
IQVIA
Charles River Laboratories
Lonza
WuXi AppTec
Syneos Health
AmerisourceBergen
Catalent
Parexel
CellCarta
Multiply Lab
Almac Group
Kelsius
Alynlyam Pharmaceutical
Legend Biotech
Gamida Cell
Bio4t2
Akkure Genomics
Deep6 AI
MatchMiner
Dassault Systèmes
Alcaris Theranostics
Quinten Health
Qiagen
PharmaLogic
Perspective Therapeutics
NH TherAguix
Clarity Pharmaceuticals
Cytiva
Multiply Labs
Takeda
CSL Behring
AstraZeneca
Brainvectis
Bluebird Bio
Intellia Therapeutics
Regeneron
Mesoblast
Replimune
Verve Therapeutics
Quell Therapeutics
Genethon
Hansa Biopharma
SonoThera
Arsenal Bioscience
Tempus
Elevate Bio
Personalis
CARsgen Therapeutics
Amgen
Ideaya Biosciences
Vertex Pharmaceuticals
Immatics
Myeloid Therapeutics
Prime Medicine
Bayer
Mammoth Biosciences
Kate Therapeutics
Mozart Therapeutics
Acepodia
ReNAgade Therapeutics
Ray Therapeutics
Convergent Therapeutics
ImmuneBridge
TORL BioTherapeutics
CARGO Therapeutics
Chroma Medicine
Resalis Therapeutics
IASO Biotherapeutics
Metagenomi
CG Oncology
Tessa Therapeutics
Engimmue Therapeutics
Swedish Orphan Biovitrum
Astellas Pharma
Sartorius Stedim Biotech
Viatris
Catalent
Galapagos
ViaCyte
Bora Pharmaceuticals
UCB
Krystal Biotech
BioNTech
Alphabet
OpenAI
C4XD
Circulogene
10xGenomics
SomaLogic
Benevolent AI
Exscientia
Allscripts
Atara Biotherapeutics
JCR Pharmaceuticals
Orchard Therapeutics
Longeveron
Daiichi Sankyo
Silence Therapeutics
Arrowhead Pharmaceuticals
Poseida Therapeutics
Beam Therapeutics
Stemirna Therapeutics
GreenLight Biosciences
NeoCura Bio-Medical Technology
Ono Pharmaceutical
TG Therapeutics
Viridian Therapeutics
Celldex Therapeutics
Exilis
Tango Therapeutics
Oncolytics Biotech.

Table of Contents

  • 1. Executive Summary

  • 2. Players

  • 3. Thematic Briefing

  • 4. Trends

    • 4.1. Healthcare trends

    • 4.2. Technology trends

    • 4.3. Macroeconomic trends

    • 4.4. Regulatory trends

  • 5. Industry Analysis

    • 5.1. Market size and growth forecasts

    • 5.2. Deals analysis

    • 5.3. Case studies

    • 5.4. Social media trends

  • 6. Value Chain

    • 6.1. Diagnostics

    • 6.2. Therapeutics

    • 6.3. Services

  • 7. Companies

    • 7.1. Public companies

    • 7.2. Private companies

  • 8. Drug Development Scorecard

  • 9. Abbreviations

  • 10. Further Reading

    • 10.1. GlobalData reports

    • 10.2. Bibliography

  • 11. About the Authors

  • 12. Our Thematic Research Methodology

  • 13. About GlobalData

  • 14. Contact Us

Frequently asked questions

Precision and Personalized Medicine in Pharma – Thematic Intelligence thematic reports
Currency USD
$1,950

Can be used by individual purchaser only

Most Popular
$2,925

Can be shared by unlimited users within one corporate location e.g. a regional office

$3,900

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Precision and Personalized Medicine in Pharma – Thematic Intelligence was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Pharmaceuticals reports
Pharmaceuticals
New
Bronchiectasis Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and…
$6,995 | May 2024
Pharmaceuticals
New
Osteoporosis Epidemiology Analysis and Forecast to 2033
$3,995 | May 2024
Pharmaceuticals
New
HER2-Positive Breast Cancer Epidemiology Analysis and Forecast to 2033
$3,995 | May 2024
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Precision and Personalized Medicine in Pharma – Thematic Intelligence in real time.

  • Access a live Precision and Personalized Medicine in Pharma – Thematic Intelligence dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more